|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||25.10 - 25.77|
|52 Week Range||20.81 - 29.93|
|PE Ratio (TTM)||42.25|
|Earnings Date||Feb 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.27|
Shares of medical device maker Boston Scientific Corporation (NYSE: BSX ) received a top-notch rating Friday from Needham. The Analyst Needham analyst Mike Matson upgraded shares of Boston Scientific from ...
NEW YORK, Dec. 05, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CME ...
Boston Scientific (BSX) announced its deal to acquire Apama Medical and strengthen its electrophysiology portfolio on October 2, 2017.
Since the company's news of the delay in relaunch of Lotus Edge on November 28, 2017, Boston Scientific (BSX) stock has fallen ~7.8%.
MARLBOROUGH, Mass. , Dec. 4, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the BMO Capital Markets Prescriptions for Success Healthcare Conference on December 14, 2017 ...
According to Boston Scientific, the delay will have no material impact on the company's fiscal 4Q17 and 2017 results.
Boston Scientific (BSX) announces a delay in deadline for the commercial return of the LOTUS Edge Aortic Valve System in Europe. Following this news, share price declines.
Boston Scientific (BSX) announced the delay in the commercialization timelines of BSX's Lotus devices in Europe and the US on November 28, 2017.
Boston Scientific dipped Wednesday after announcing another delay for its heart-valve replacement product, called Lotus Edge.
Shares of the worldwide developer, manufacturer, and marketer of medical devices were sent lower on Tuesday after it delayed the commercialization of its Lotus Edge Aortic Valve System.
Boston Scientific’s Cardiovascular segment accounts for around 40% of the company’s value, according to our estimates.
Boston Scientific Corporation (NYSE: BSX ) announced Tuesday after the close a delay to earlier timelines that were established for commercialization of the LOTUS Edge Aortic Valve System in Europe and ...
Shares of Boston Scientific took an unexpected dive on Tuesday after the Marlborough-based medical device maker cancelled a scheduled appearance at an investor conference without explanation. Boston Scientific (BSX) pulled out of the annual Piper Jaffray healthcare conference in New York, where two of the company’s investor relations executives had been scheduled to participate in a question-and-answer session Tuesday morning.
MARLBOROUGH, Mass., Nov. 28, 2017 /PRNewswire/ -- Boston Scientific (BSX) announces a delay to previously communicated timelines for commercialization of the LOTUS Edge™ Aortic Valve System* in Europe and the U.S. The company now expects to provide an update on the status of the LOTUS Edge Valve during its fourth quarter 2017 earnings conference call on February 1, 2018, as it continues to focus on manufacturing and regulatory milestones to support the long-term success of the Lotus platform. "We continue to see value in the unique benefits of the LOTUS Valve platform in treating patients with aortic stenosis," said Mike Mahoney, chairman and chief executive officer, Boston Scientific.
Boston Scientific (BSX) fell to the bottom of the S&P 500 on Tuesday, after it pulled out of a scheduled conference appearance. Boston Scientific slid $2.12, or $7.4, to $26.42, while the S&P 500 rose 25.62 points, or 0.98%, to 2627.04, notching a new record close. As last as last week, Boston Scientific had been scheduled to appear at the Piper Jaffary Annual Healthcare Conference.
Stock Monitor: Medtronic Post Earnings Reporting LONDON, UK / ACCESSWIRE / November 28, 2017 / Active-Investors' free earnings report on Boston Scientific Corp. (NYSE: BSX ) has freshly been issued to ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Boston Scientific Corp. Here are 5 ETFs with the largest exposure to BSX-US. Comparing the performance and risk of Boston Scientific Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
MARLBOROUGH, Mass. , Nov. 27, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the Citi 2017 Global Healthcare Conference on December 7, 2017 in New York . Kevin Ballinger ...
Four months after losing its longtime chief financial officer to another drugmaker, Biogen has appointed a former Boston Scientific executive to that post. Cambridge-based Biogen (BIIB) said Tuesday that Jeffrey Capello will take over as CFO on Dec. 11. Before that, he founded and ran his own financial advisory firm in Boston, and held CFO roles at Ortho Clinical Diagnostics, Boston Scientific Corp. (BSX) and PerkinElmer (PKI).
In August of last year, yours truly here commented that fitness tracker company Fitbit Inc (NYSE:FIT) was a lost cause by catering to the consumer fitness market, and would only survive if it pivoted to being a full-blown medical device company. The response from loyal owners of FIT stock was…colorful, explaining such a thing could never happen, nor did it need to. Here we are 15 months later, and the FIT stock price is 60% less than its value then.